GLP-1 receptor agonists are the most consequential drug class to emerge in obesity and type-2 diabetes since metformin. The category started with exenatide and liraglutide, broke commercial ceilings with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and is now expanding into orals (orforglipron, oral semaglutide), triple agonists (retatrutide), and amylin combinations (cagrisema, eloralintide).
The signal worth tracking has shifted. Weight loss alone is no longer the headline — secondary indications are. SELECT showed a 20% drop in major adverse cardiovascular events for non-diabetic adults with obesity. A Mass General Brigham analysis in JAMA reported 42–58% lower heart-failure hospitalizations in HFpEF. AAN 2026 added migraine, dementia incidence, and Parkinson's signals to the growing list. The Phase 3 EVOKE Alzheimer's trial, by contrast, missed its endpoint.
Gallup's July 7, 2026 poll release documented the first large-population evidence that GLP-1 uptake is bending the US obesity curve: 11% of US adults now take a GLP-1 for weight loss (up from 3% in 2024 and 8% in 2025), and the US adult obesity rate has drifted from a 2022 peak of 39.9% down to 36.4% in 2026. Awareness climbed from 80% to 91% over the same span. Browse the latest below, or filter by drug at #semaglutide, #tirzepatide, #orforglipron, and #retatrutide.
Novo Nordisk announced on Monday, September 14, 2026 that it will use 'Novo' as its day-to-day company name, while Novo Nordisk A/S remains its legal name. The rebrand introduces the platform 'Lasting Health Starts Now,' an updated version of the Apis bull logo, and a culture framework called The Novo Way, built on customer obsession, competitiveness, clarity, and care and integrity. CEO Mike Doustdar said healthcare "must become more responsive, relevant and easier to fit into everyday life." The company said it would present more detail on its strategy at its Capital Markets Day in London on September 21, 2026.
Novo Nordisk and Anthropic announced on Wednesday, September 16, 2026 a collaboration under which Novo Nordisk will test Anthropic's Claude Science in specific research and development workflows and use Anthropic's frontier models for biological reasoning, drug discovery, and AI-driven software development. Financial terms were not disclosed. Novo Nordisk CEO Mike Doustdar said AI can help the company increase R&D productivity and "compress the path from research to marketed product." Anthropic co-founder and CEO Dario Amodei said giving researchers access to frontier models can shorten research timelines.
Novo Nordisk said on Wednesday, September 16, 2026 that it will present 44 abstracts at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from September 28 to October 2. The OCTANE study will report real-world data on Wegovy pill use, including weight outcomes, treatment switching, and patient-reported outcomes. Other presentations cover Wegovy 7.2 mg; CagriSema (cagrilintide plus semaglutide) data on appetite regulation, eating behavior, body composition, and bone remodeling from the REDEFINE and REIMAGINE programs; and zenagamtide, the unimolecular GLP-1 and amylin receptor agonist formerly called amycretin.
STAT News published Tuesday September 15, 2026 a landscape piece flagging that obesity drug developers have expanded pediatric trial testing to include children as young as six years old, extending the age range down from the Wegovy 12-and-older U.S. label. Novo Nordisk's STEP Young Phase 3 (topline reported September 7) tested once-weekly semaglutide in 165 children aged 6 to under 12 with obesity: 40.4% of the semaglutide group achieved a BMI below the obesity threshold at week 68 versus 0% on placebo, with no new safety concerns and no signals for growth or pubertal development. STAT flagged additional pediatric-obesity trial activity following the January 2023 AAP Clinical Practice Guideline endorsement of medication therapy for children aged 12+ and consideration in ages 6-11. The September 4 Pediatrics journal publication documented a 310-fold increase in GLP-1 prescribing to U.S. children aged 8-11 with obesity between 2019 and mid-2026 (0.03% to 9.3%), with 93.7% of recipients having severe obesity and 65.2% having weight-related comorbidities. Full STEP Young results are scheduled for ObesityWeek 2026 (November 14-17, Washington DC). No Wegovy sNDA for ages under 12 has been filed as of September 15, 2026.
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) heads into the week of September 14-19, 2026 with the September 21 Capital Markets Day in London one week away, and Friday September 11 fresh in investor minds. Morgan Stanley analyst Thibault Boutherin had cut Novo Nordisk to Underweight from Equal-weight Friday with a DKK 250 price target (implying more than 10% downside) citing subdued mid-term growth outlook plus concerns about the semaglutide loss-of-exclusivity beginning 2031 (semaglutide accounts for approximately 75% of Novo's 2026 sales). HSBC on Wednesday September 9 had raised its price target to DKK 320 (Hold), and Barclays on September 8 had trimmed its target to DKK 300 (Equal Weight). Novo shares closed the prior week down 2.8% in Copenhagen at DKK 278.2. The London Capital Markets Day is expected to unveil fresh strategic ambitions to replace existing targets, plus pipeline detail on CagriSema (cagrilintide + semaglutide) after the February 2026 Redefine-1 head-to-head miss versus Zepbound (23% vs 25.5% weight loss), amycretin (GLP-1/amylin unimolecular dual agonist Phase 3 planning), and the post-semaglutide non-GLP-1 diversification story after the September 7 HERMES + ATHENA ziltivekimab heart-failure trial terminations.
Morgan Stanley analyst Thibault Boutherin and team cut Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) to Underweight from Equal-weight on Friday September 11, 2026, with a DKK 250 price target implying more than 10% downside from current levels. The downgrade thesis: Novo's current valuation does not fully reflect the subdued mid-term growth outlook or the semaglutide patent-cliff implications on the company's terminal value. Semaglutide is expected to account for approximately 75% of Novo's 2026 sales; loss of exclusivity begins in 2031 across major markets. Morgan Stanley also flagged weaker momentum in U.S. Wegovy pill prescriptions following a stronger first half of 2026. Novo shares closed the week down 2.8% in Copenhagen at DKK 278.2 and 3.1% in Frankfurt at EUR 36.89. HSBC on Wednesday September 9 had raised its price target to DKK 320 (from DKK 300) while maintaining a Hold rating, framing the analyst split. Barclays cut its price target to DKK 300 from DKK 310 September 8 following the STEP Young + ziltivekimab HERMES/ATHENA split announcement, and Guggenheim earlier moved its target on Roivant/Pulmovant PHocus success. Novo executed DKK 9.02 billion of the DKK 15 billion share repurchase through September 4.
A systematic review and meta-analysis of head-to-head comparisons of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy) in adults with overweight or obesity — published in Diabetes, Obesity and Metabolism and covered by Medscape on September 9, 2026 with running weekend commentary — synthesized 10 studies (three randomized controlled trials and seven retrospective cohort studies) enrolling 41,381 adults. Tirzepatide produced a mean 4.28 percentage-point greater percent-body-weight reduction than semaglutide (10 studies) and a mean 4.43 kg greater absolute weight loss (8 studies). One head-to-head study reported average weight loss of 50.3 lbs (22.9 kg) on tirzepatide versus 33.1 lbs on semaglutide. Gastrointestinal adverse events were common in both arms but somewhat more frequent with tirzepatide; serious adverse event rates were rare but higher on tirzepatide than semaglutide. The pooled evidence supports the SURMOUNT-5 head-to-head randomized readout published in the New England Journal of Medicine in 2025 (Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks). The tirzepatide-semaglutide efficacy gap plus the safety trade-off remains a live clinical decision point in a market where 12%+ of U.S. adults are on the GLP-1 class per recent surveys.
The oral GLP-1 launch race entered its ninth month with Novo Nordisk's Wegovy pill (oral semaglutide 25 mg for chronic weight management, U.S. launch January 5, 2026) reaching approximately 183,000 weekly total scripts per the most recent IQVIA week ending September 5, 2026 — the highest weekly total since launch. Eli Lilly's Foundayo (orforglipron, once-daily oral small-molecule non-peptide GLP-1 receptor agonist, U.S. launch April 2026) continued its own prescription climb through the same reporting window. Both products are indicated for adults with obesity or overweight with weight-related comorbidities. Wegovy pill's climb reflects continued Medicare Part D coverage expansion following the November 2025 pricing agreement (Ozempic Pill / Wegovy pill at $149/month per the deal) and CMS 2026 formulary guidance. Foundayo pricing on TrumpRx and cash-pay LillyDirect anchors at $149/month at starting doses. The concurrent oral launch trajectories are the largest test to date of oral incretin adoption relative to the established weekly-injectable class dominated by injectable Wegovy and Zepbound.
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) shares closed at DKK 298.95 in Copenhagen on Monday September 7, 2026 (roughly 1.9% below Friday) after the company's simultaneous release of STEP Young Phase 3 pediatric semaglutide data (40.4% of children aged 6 to under 12 achieved BMI below the obesity threshold at week 68 versus 0% placebo) and confirmation that the HERMES and ATHENA Phase 3 ziltivekimab (anti-IL-6 monoclonal antibody) heart-failure trials had been terminated early after a data monitoring committee ruled the studies unlikely to succeed. Barclays' James Gordon cut the Novo Nordisk price target from DKK 310 to DKK 300 while maintaining an Equal Weight rating. Analyst commentary broadly framed the day as a scientific-engine-versus-diversification tension: the semaglutide franchise continues to add indication paths (pediatric obesity below 12 years is one of the last major label extensions available), while the non-GLP-1 diversification story tied to ziltivekimab now depends primarily on the post-acute heart-failure study that remains ongoing. Detailed STEP Young results will be presented at ObesityWeek 2026 in Washington DC November 14-17.
Novo Nordisk (NYSE: NVO) announced Monday September 7, 2026 first results from STEP Young, a Phase 3 randomized double-blind placebo-controlled multinational trial evaluating once-weekly semaglutide combined with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity. The trial enrolled 165 children, dosed with a maximum of 1.7 mg or 2.4 mg semaglutide based on baseline weight. At week 68, 40.4% of the semaglutide group had a BMI below the obesity threshold versus 0% in the placebo group; more than 85% of enrolled children had class II or III severe obesity (BMI ≥35 or ≥40 by adult equivalents) at baseline. Safety and tolerability were consistent with adult and adolescent trials with no new safety concerns and no signals related to growth or pubertal development. Detailed results will be presented at ObesityWeek 2026 in Washington DC November 14-17. Wegovy is currently approved in the U.S. for adolescents 12 and older; a supplemental submission for children under 12 has not been announced.
A CROI 2026 (Conference on Retroviruses and Opportunistic Infections) analysis presented earlier in 2026 documented that GLP-1 weight-loss medications generally work well for people living with HIV who are stable on antiretroviral therapy. Beyond the known obesity and type 2 diabetes benefits, the CROI analysis reported potential improvements in liver, gut, and cardiovascular health, plus reduced smoking rates in the HIV population on GLP-1 therapy. Real-world analysis of people living with HIV prescribed semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound) documented comparable weight loss to general-population Phase 3 trial data with no new safety signals specific to the HIV population. Approximately 40% of people living with HIV in the US also have obesity, and cardiovascular disease is one of the primary drivers of morbidity and mortality in the HIV-treated population. The CROI analysis supports GLP-1 therapy as a reasonable consideration in HIV patients with obesity or metabolic-syndrome comorbidities, particularly following the AIDS 2026 conference programming that concluded Friday July 31 in Rio de Janeiro emphasizing the sustained management of HIV alongside comorbid conditions in the current global funding-constrained environment. The finding also intersects with the ongoing peptide-adjacent HIV therapeutic landscape covered by the July 2026 Gilead-Merck ISLEND-1 and ISLEND-2 once-weekly islatravir/lenacapavir data and the Merck alimatravir monthly HIV prevention pill.
Medscape published an emulated randomized trial analysis on Tuesday July 28, 2026 using US insurance claims data from 2018-2023 to test whether patients with stable inflammatory bowel disease (IBD) and comorbid obesity or diabetes benefit from initiating GLP-1 receptor agonist therapy alongside their ongoing IBD treatment. The researchers used a target trial emulation design comparing patients who initiated semaglutide or tirzepatide with patients who did not. Two cohorts were analyzed: Cohort 1 comprised patients on 5-aminosalicylates or no IBD-related therapy; Cohort 2 comprised patients on immunomodulators and/or advanced therapies (biologics or small molecules). Neither cohort showed a lower risk of IBD relapse or improved safety event rates among GLP-1 initiators. The analysis pushes back against the anti-inflammatory hypothesis advanced in preclinical GLP-1 receptor agonist literature (based on animal-model reductions in gut inflammation) and against the informal clinical assumption that IBD patients with obesity or diabetes may derive an anti-inflammatory benefit from initiating GLP-1 therapy. The clinical implication: prescribers should not initiate GLP-1 receptor agonist therapy in stable IBD patients for the purpose of improving IBD outcomes. GLP-1 initiation for obesity or diabetes in this population remains reasonable when the metabolic indication justifies it independently.
Australia's Therapeutics Goods Administration (TGA) issued a class-wide product warning update Saturday July 25, 2026 for GLP-1 receptor agonists on non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but severe form of eye disorder that may result in permanent visual impairment including blindness. No treatment has been shown to improve visual acuity outcomes after NAION onset. The label update applies across all five GLP-1 RA products currently marketed in Australia: Trulicity (dulaglutide, Eli Lilly), Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk), Mounjaro (tirzepatide, Eli Lilly), and Saxenda (liraglutide, Novo Nordisk). The Advisory Committee on Medicines concluded that the current evidence supports the signal for semaglutide but not for dulaglutide or tirzepatide. A search of the Australian Database of Adverse Event Notifications (DAEN) found 36 cases of optic ischaemic neuropathy with GLP-1 RAs, including 23 for semaglutide, 10 for tirzepatide, and 3 for liraglutide. Patient guidance advises seeking urgent medical attention for any sudden vision loss including partial loss of vision. The Australian action follows the UK MHRA Drug Safety Update on semaglutide and NAION issued February 5, 2026.
JAMA Pediatrics published a UT Southwestern Medical Center retrospective cohort study Monday July 20, 2026 examining GLP-1 receptor agonist and metabolic and bariatric surgery (MBS) utilization patterns among 204,000+ US adolescents and young adults ages 13-25 treated for obesity between May 2022 and January 2026 in the Epic Cosmos electronic health record database. Key findings: the share of patients using only GLP-1 drugs rose from 88.2% (May-November 2022) to 96.1% (June 2025-January 2026); the share of patients undergoing MBS fell from 11.6% to 3.7% over the same window; combined GLP-1 + MBS use remained rare at approximately 0.2%. The study documents a substitution effect from surgical obesity treatment toward pharmacologic obesity treatment in the youth population over 44 months of coverage. Context: severe obesity currently affects approximately 9% of US adolescents ages 12-18. The findings raise questions about long-term efficacy, weight-regain risk after GLP-1 discontinuation in adolescents, and the appropriate role of MBS in adolescents whose obesity is unresponsive to GLP-1 pharmacotherapy. The study covers the pediatric analog of the earlier adult utilization-shift patterns already documented in the Kaiser Permanente and Optum electronic health record data.
Novo Nordisk (NYSE: NVO) filed a federal lawsuit Tuesday July 21, 2026 against Eli Lilly (NYSE: LLY) alleging that Lilly has run 'deceptive' advertising campaigns for its GLP-1 drugs Zepbound and Mounjaro (both tirzepatide), per STAT News reporting. The Novo complaint reportedly targets marketing claims that make Lilly's tirzepatide franchise appear more effective than the underlying clinical data support relative to Novo's Wegovy and Ozempic (both semaglutide). The lawsuit arrives against a competitive backdrop where Lilly has been extending its US commercial lead in the obesity market: Q1 2026 sales showed Mounjaro at $8.7 billion (up 125% year-over-year) and Zepbound at $4.2 billion (up 80%), while Novo Nordisk faced flat-to-declining semaglutide revenue after March 2026 price cuts, and Lilly overtook Novo in US GLP-1 market share. The SURMOUNT-5 head-to-head Phase 3 trial published earlier in 2026 showed superior efficacy for tirzepatide over semaglutide on weight loss endpoints; Novo's complaint appears to focus on how Lilly extrapolates the SURMOUNT-5 comparative data into consumer-facing advertising. The dispute frames the GLP-1 marketing battlefield ahead of Q2 earnings reports (Lilly August 5, Novo August 6).
Samsung Biologics announced Sunday-Monday July 19-20, 2026 an all-cash public tender offer to acquire Switzerland's PolyPeptide Group for CHF 1.46 billion ($1.8 billion) at CHF 44.31 per share, a 40% premium to the undisturbed share price of CHF 31.65. The transaction represents the largest biopharmaceutical M&A in South Korean history. Strategic rationale: PolyPeptide is a global peptide contract development and manufacturing organization (CDMO) with accelerating revenue growth driven by rising client demand for peptide-based GLP-1 therapies for obesity and diabetes. The acquisition expands Samsung Biologics' capabilities beyond monoclonal antibody manufacturing (its historical strength) into peptide therapeutics and adds PolyPeptide's global network spanning Sweden, Belgium, France, the United States, and India, encompassing R&D, development, and commercial manufacturing capabilities. PolyPeptide's Board of Directors unanimously recommends the offer. The largest shareholder has given an irrevocable tender undertaking representing approximately 55.65% of outstanding shares. Samsung Biologics expects to complete the deal by end of 2026. The deal extends the July 2026 peptide-manufacturing consolidation wave alongside Novartis's $1.5 billion Myricx Bio acquisition (ADC payloads, July 6) and Lonza's Nona Biosciences TfR1 blood-brain-barrier deal (July 2).
General Bio, a developer of oral GLP-1s and other peptides, has raised $7.4 million and is pursuing a larger follow-on funding round, CEO David Kim told Axios Pro Biotech Deals in an exclusive report published Monday July 20, 2026. The company is one of several new-generation oral peptide startups seeking to compete against the established oral-peptide market, which now spans Novo Nordisk's Wegovy pill (oral semaglutide 25 mg, launched January 2026, over 3 million US prescriptions by June), Merck's LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor FDA-approved July 16, 2026), and MindRank AI's MDR-001 (AI-designed oral small-molecule GLP-1RA in Phase 3 MOBILE trial in China, $52M Series B closed July 9). The oral peptide category economics are shaped by macrocyclic peptide chemistry (Merck's LIPFENDRA approach) that allows survival through the gastrointestinal tract, permeation-enhancer formulations (Novo's SNAC technology for oral semaglutide), and next-generation delivery platforms including Rani Therapeutics' RaniPill capsule (July 9 collaboration announced with China's PegBio). Seed-stage entrants like General Bio typically position on proprietary chemistry or delivery mechanisms that could enable next-generation peptides beyond the current oral GLP-1 wave.
STAT News published a major investigation Monday July 20, 2026 reporting that LifeMD, a US telehealth company promoted by Novo Nordisk as a partner for Wegovy and Ozempic access, has pushed clinicians to see more patients and dispense GLP-1 prescriptions more rapidly while providing what former workers describe as minimal screening and follow-up. Five former employees and two lawsuits filed by former top leaders allege that providers at LifeMD were pressed to review up to 25 patient cases per hour based only on the electronic intake forms patients themselves filled out, translating to approximately two minutes per case. Novo Nordisk currently lists LifeMD on its website as a partner that offers 'legitimate medicine sourcing and patient support' for people seeking GLP-1 drugs. LifeMD strenuously denies the allegations. The reporting extends the June-July concern set documented by the JAMA secret-shopper study (45 of 49 online sellers wrote semaglutide or tirzepatide prescriptions within a day with limited clinical oversight, July 7 digest coverage) and complements the peptide-telehealth-landscape reporting the site has tracked through 2026. The LifeMD story sits within the sprawling loosely-regulated GLP-1 telehealth industry that experts say has been boosted by Novo Nordisk and Eli Lilly as branded-drug demand expanded through 2025 and 2026.